Generic Minolira Availability
Last updated on May 7, 2025.
Minolira is a brand name of minocycline, approved by the FDA in the following formulation(s):
MINOLIRA (minocycline hydrochloride - tablet, extended release;oral)
-
Manufacturer: EPI HLTH
Approval date: May 8, 2017
Strength(s): EQ 105MG BASE (discontinued), EQ 135MG BASE (discontinued)
All of the above formulations have been discontinued.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Minolira. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Pharmaceutical compositions for minocycline
Patent 11,103,517
Issued: August 31, 2021
Inventor(s): Lowalekar Rohit & Padhi Bijay Kumar & Raghuvanshi Rajeev Singh
Assignee(s): DR. REDDY'S LABORATORIES LTD.The present application relates to a method of orally administering once daily tablet of minocycline to a subject in need thereof, wherein said tablet is substantially free of lactose. The present application also relates to processes for preparing said once daily tablet of minocycline that provides reduced stock keeping units with improved inventory by supplying multiple doses of minocycline in single tablet.
Patent expiration dates:
- April 7, 2036✓
- April 7, 2036
More about Minolira (minocycline)
- Minolira consumer information
- Check interactions
- Compare alternatives
- Imprints, shape & color data
- Side effects
- Dosage information
- During pregnancy
- Drug class: tetracyclines
- Breastfeeding
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.